[Sing Tao Daily Report]Meng Weining, vice president of Zhongwei Biotechnology of Kexing Holdings, said that in December last year, the company had obtained the new Crown Omicron mutant virus strain through cooperation with the Hong Kong Government and universities to help develop a new generation of vaccines. At this stage, animal experiments have had ideal results. It is hoped that clinical tests will be carried out in some countries this month. After obtaining sufficient data next month, vaccines once morest Omicron mutant viruses will be supplied worldwide by May.
Meng Weining pointed out that according to Chilean data from June to December last year, Kexing vaccine is very safe for children between the ages of 6 and 11, including dealing with the Delta mutant virus strain. The incidence rate of two doses of vaccine prevention reached 76%, and the proportion of hospitalization prevention reached 87.6%. In terms of pregnant women, according to Brazilian data last year, there were 15.8 reports of sudden miscarriage per 100,000 doses following vaccination with Kexing, and regarding 142 cases of Astrazeneca vaccine, which is the lowest among the four vaccines. As for the proportion of serious side effects, fever and headache among pregnant women following vaccination with Kexing, it is also lower than other vaccines.
Download now｜The new “Sing Tao Headlines” APP:https://bit.ly/3yLrgYZ
